Physician profile
Mark Livezey
NPI 1477524312
$2,665.58
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,545 · 2020: $1,121.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $800.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $460.74 | 2019-2020 | |
| Genentech USA, INC. | $333.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $226.34 | 2019-2020 | |
| Pfizer INC. | $209.33 | 2019-2020 | |
| Glaxosmithkline, LLC. | $188.80 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $128.13 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.21 | 2019-2020 | |
| Grifols USA, LLC | $42.02 | 2019 | |
| Covis Pharma Gmbh | $39.42 | 2019 | |
| Kaleo, INC. | $32.37 | 2019 | |
| Csl Behring | $31.57 | 2019 | |
| Genzyme Corporation | $22.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.96 | 2019 | |
| Alk-Abello, INC | $16.73 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $16.25 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Livezey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.